GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Other Long-Term Liabilities

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Other Long-Term Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Other Long-Term Liabilities?

Verrica Pharmaceuticals's other long-term liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Verrica Pharmaceuticals's quarterly other long-term liabilities stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

Verrica Pharmaceuticals's annual other long-term liabilities declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).


Verrica Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Verrica Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Other Long-Term Liabilities Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial - - - - -

Verrica Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Verrica Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.


Verrica Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals (Verrica Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ted White director, officer: President and CEO C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes officer: General Counsel C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso officer: Chief Commercial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Gary Goldenberg director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson 10 percent owner C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk officer: Chief Operating Officer 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Verrica Pharmaceuticals (Verrica Pharmaceuticals) Headlines

From GuruFocus

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-09-2023